Author: ["Alash'le G. Abimiku","Genoveffa Franchini","James Tartaglia","Kristine Aldrich","Maria Myagkikh","Phillip D. Markham","Pele Chong","Michel Klein","Marie-Paule Kieny","Enzo Paoletti","Robert C. Gallo","Marjorie Robert-Guroff"]
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Rhesus macaques were immunized with attenuated vaccinia or canarypox human immunodeficiency virus type 1 (HIV-1) recombinants and boosted with HIV-1 protein subunits formulated in alum. Following challenge with HIV-2SBL6669, three out of eight immunized macaques resisted infection for six months and another exhibited significantly delayed infection, whereas all three naive controls became infected. Immunizations elicited both humoral and cellular immune responses; however, no clear correlates of protection were discerned. Although more extensive studies are now called for, this first demonstration of cross-protection between HIV-1 and -2 suggests that viral variability may not be an insurmountable problem in the design of a global AIDS vaccine.Cite this article
Abimiku, A., Franchini, G., Tartaglia, J. et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1, 321–329 (1995). https://doi.org/10.1038/nm0495-321 